PARP1 and head and neck squamous cell carcinoma: Animal investigations indicate that using the PARP inhibitor Olaparib and the DNA-PK inhibitor NU7441 in conjunction with ionizing radiation boosts the suppression of HPV-negative head and neck squamous cell cancer (HNSCC), indicating that this may be a useful and novel approach to treating cases with HPV-negative HNSCC (Zeng et al., 2020).